Long-Term Amerlioration of Bilirubin Glucuronidation Defect in Gunn Rats by Transplanting Genetically Modified Immortalized Autologous Hepatocytes

1998 ◽  
Vol 7 (6) ◽  
pp. 607-616 ◽  
Author(s):  
Kouji Tada ◽  
Namita Roy-Chowdhury ◽  
Vinayaka Prasad ◽  
Byung-Ho Kim ◽  
P. Manchikalapudi ◽  
...  
Cytotherapy ◽  
2021 ◽  
Vol 23 (5) ◽  
pp. S151
Author(s):  
I.N. Muhsen ◽  
D. Steffin ◽  
N. Ahmed ◽  
M. Hegde ◽  
O. Dakhova ◽  
...  

2007 ◽  
Vol 15 (9) ◽  
pp. 1670-1676 ◽  
Author(s):  
Fernando Larcher ◽  
Elena Dellambra ◽  
Laura Rico ◽  
Sergio Bondanza ◽  
Rodolfo Murillas ◽  
...  

2021 ◽  
Author(s):  
Corbin E. Goerlich ◽  
Bartley P. Griffith ◽  
John A. Treffalls ◽  
Tianshu Zhang ◽  
Avneesh K. Singh ◽  
...  

Abstract There are 5.7 million people in the United States with heart failure, which is life-limiting in 20% of patients.1 While data is most robust in the United States for this cohort, it is known to be a global problem with over 23 million people carrying the diagnosis.1 For end-stage heart failure, many require a heart transplantation, however, there is a shortage in the supply of organ donors. Cardiac xenotransplantation has been proposed to “bridge the gap” in supply for these patients requiring transplantation. Recent pre-clinical success using genetically modified pig donors in baboon recipients has demonstrated survival greater than 6 months.2–5 First-in-human transplantation of a genetically modified pig kidney demonstrated 54 hour rejection-free function when perfused by a deceased human recipient, demonstrating the feasibility of cross-species transplantation and invigorating enthusiasm further to utilize this new organ source for a population that would otherwise die waiting for a human organ.6 While this human study demonstrated proof-of-principle of overcoming hyperacute rejection, further regulatory oversight by Food and Drug Administration (FDA) may be required with pre-clinical trials in large animal models of xenotransplantation with long-term survival. These studies not only require a multi-disciplinary team and expertise in orthotopic transplantation (cardiac surgery, anesthesia and cardiopulmonary bypass), immunology and genetic engineering; but also, specifically handling large animal recipients that cannot communicate their symptoms. Here we detail our approach to pig-to-primate large animal model of orthotopic cardiac xenotransplantation perioperatively and in the months thereafter in long-term surviving animals. We also detail xenograft surveillance methods and common issues that arise in the postoperative period specific to this model and ways to overcome them.


Sign in / Sign up

Export Citation Format

Share Document